Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind placebo-controlled phase 3 study of low-dose estriol vaginal gel (ITFE-2026 0.005%) for postmenopausal vaginal atrophy
2007-003399-20Phase 3Completed
- Sponsor
- Italfarmaco
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vaginal atrophy comparing ITFE-2026 estriol vaginal gel 0.005% with Placebo vaginal gel (2 arms). Primary endpoint: Change in vaginal maturation index at 12 weeks. Started Nov 2007; status: completed.
02
Drugs
estriol
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on 2007-003399-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003399-20.